CAJ | 학술논문

非小细胞肺癌(non-small cell lung cancer，NSCLC)的分子靶向治疗是目前的研究热点，继EGFR、ALK基因等靶点之后不断有新的肿瘤标志物被发现。ROS1基因重排作为一种新发现的NSCLC亚型，其发生率约占NSCLC的1%~2%，优势人群通常为年轻、不吸烟的肺腺癌患者，这些临床特征与ALK重排的NSCLC患者类似。本文将NSCLC中发现的ROS1融合基因的研究进展及其在NSCLC中的临床、功能和结构特征进行阐述。
비소세포폐암(non-small cell lung cancer，NSCLC)적분자파향치료시목전적연구열점，계EGFR、ALK기인등파점지후불단유신적종류표지물피발현。ROS1기인중배작위일충신발현적NSCLC아형，기발생솔약점NSCLC적1%~2%，우세인군통상위년경、불흡연적폐선암환자，저사림상특정여ALK중배적NSCLC환자유사。본문장NSCLC중발현적ROS1융합기인적연구진전급기재NSCLC중적림상、공능화결구특정진행천술。
Molecular target therapy has become a hot research direction of non-small cell lung cancer (NSCLC) treatment. New tumor markers are continually found atfer EGFR and ALK genes. ROS1 rearrangement deifnes a new mo-lecular subset of NSCLC with the prevalence of ROS1 rearrangements around 1%~2%. NSCLC patients with ROS1 rearrangement arise in young never-smokers with adenocarcinoma that are similar to those observed in patients with ALK-rearranged NSCLC. hTe article reviews research progress of ROS1 fusion gene and clinical/functional/structural characteristics of this fusion gene in NSCLC patients.